SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

ARVN

Arvinas Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed13d 20h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming clinical data presentations for ARV-393 at ASH in December 2026 and ARV-027/ARV-6723 data in 2027, as these are the primary value drivers for this pre-commercial biotech. Cash runway into H2 2028 provides a long operational runway but no near-term revenue catalyst.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

ARVN drug pipeline →

ARV-393

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
At least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.
Next catalyst
None dated

What to watchThe next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$7.09
T+0 close · Nov 3, 2026 · via day close
Latest settled
−2.40%
T+5 · $6.92 · next T+20 in 15d
Vs SPY
−1.81%
α at T+5
Latest observation
−2.97%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $7.09entry
  2. T+1 · 13d ago +4.65%α +3.00% · $7.42
  3. T+5 · 7d ago −2.40%α −1.81% · $6.92
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas reported Q3 2026 revenue of $0.5M, down from $41.9M a year ago, as Pfizer collaboration revenue did not recur following the Rigel license. GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS of -$0.95, a beat on the bottom line. The company highlighted upcoming clinical data readouts for ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, and reiterated its cash runway into H2 2028.

Key Financial Metrics

EPS
−$0.82
est −$0.95 · +13.7%
Revenue
$500.0K
-98.8% YoY
Rating
beat

Key Facts

  • Q3 2026 revenue was $0.5M vs. $41.9M in Q3 2025; the decrease was driven by non-recurrence of Pfizer collaboration revenue and milestone payments.
  • GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS estimate of -$0.95, a beat.
  • Cash, cash equivalents, restricted cash, and marketable securities were $558.9M as of September 30, 2026, down from $685.4M at year-end 2025.
  • R&D expenses decreased to $46.9M from $64.7M year-over-year, primarily due to lower external and personnel costs.
  • Company expects cash runway into the second half of 2028.
  • Initiated dosing in Phase 1/2 trial of ARV-6723 (HPK1 degrader) and Phase 1 trial of ARV-027 (polyQ-AR degrader) in healthy volunteers.
  • Upcoming milestones include ARV-393 monotherapy data at ASH (Q4 2026), ARV-027 initial data (1H 2027), and ARV-6723 initial monotherapy data (2H 2027).

Financial Impact

Revenue declined $41.4M YoY; net loss of $53.9M vs. $35.1M loss in Q3 2025; cash burn of $126.5M in nine months.

revenuenet losscash position

Risk Factors

  • Revenue collapsed to near-zero after Pfizer collaboration revenue ended; reliance on Rigel royalties is minimal ($0.5M).
  • All pipeline candidates are in early-stage clinical trials with no approved products; clinical failure risk is high.
  • IND for ARV-102 remains on hold in the U.S., limiting the addressable patient population for the PSP trial.
  • document contains text addressed to automated readers

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394044

Track record

21 reports on ARVN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Viewing Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026